MedTrace Logo

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

NCT03195569 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2017-06-22

No results posted yet for this study

Summary

To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the study of QL1101 and Avastin® in patients with Non-squamous Non-small Cell Lung Cancer

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

QL1101

targeted vascular endothelial growth factor (VEGF) monoclonal antibodies

DRUG

Avastin®

targeted vascular endothelial growth factor (VEGF) monoclonal antibodies

DRUG

Paclitaxel

175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.

DRUG

Carboplatin

AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    collaborator OTHER

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-06-12
Completion
2018-12-10
FDA Drug
Yes

Countries

  • China

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03195569 on ClinicalTrials.gov